Abstract
Ramipril has been used in twice daily dose of 5 mg in most heart failure trials, whereas the dose used in Heart Outcomes Prevention Evaluation (HOPE) study was 10 mg once at bedtime. The HOPE investigators in an ambulatory blood pressure (ABP) substudy observed a fall of nighttime but not daytime blood pressure (BP). We examined the effects of once daily ramipril 10 mg versus 5 mg twice a day. Twenty-nine patients were recruited based on the original criteria for the HOPE study and were given ramipril either in twice-daily dose (5 mg b.d.) or once daily (10 mg o.d.) each morning in randomized, prospective crossover trial. Twenty-four hour ABP recordings were taken just before commencement of ramipril therapy and after treatment with twice-daily and once-daily ramipril. Our results show that ramipril causes a significant reduction of BP over 24-h period as compared with baseline. The mean baseline ABP was 124/73 mm Hg, which reduced to 117/69 mm Hg for the twice-a-day regimen (P<0.001) and 115/68 mm Hg for the once a day regimen (P<0.001). Both regimes effectively lower BP to a similar extent. Ramipril causes significant BP reduction in both once- and twice-daily dosing. The fall in BP after daytime dosing is greater than that observed in the HOPE study (including ABP substudy). Once-daily dosing in the morning seems to be effective in causing a significant reduction in the ABP profile of patients at high-risk of a future vascular event.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–153.
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J, Heart Outcomes Prevention Evaluation (HOPE) Study. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130–2131.
Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.
Thuillez C, Richer C, Giudicelli JF . Pharmacokinetics, converting enzyme inhibition and peripheral arterial haemodynamics of ramipril in healthy volunteers. Am J Cardiol 1987; 59: 38D–44D.
Meyer BH, Muller FO, Badian M, Eckert HG, Hajdu P, Irmisch R et al. Pharmacokinetics of ramipril in the elderly. Am J Cardiol 1987; 59: 33D–37D.
Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, Kuan TS et al. Influence of renal function on the pharmacokinetics of ramipril (HOE498). Am J Cardiol 1987; 59: 70D–78D.
Schunkert H, Kindler J, Gassmann M, Lahn W, Irmisch R, Debusmann ER et al. Steady-state kinetics of ramipril in renal failure. J Cardiovasc Pharmacol 1989; 13: S52–S54.
The AIRE Study Investigators. Effect of Ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828.
Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J . Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001; 38: e28–e32.
Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528–536.
Goyal D, MacFadyen RJ, Watson R, Lip GYH . Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Failure 2005; 7: 149–156.
Coats AJ, Conway J, Somers VK, Isea JE, Sleight P . Ambulatory pressure monitoring in the assessment of antihypertensive therapy. Cardiovasc Drugs Ther 1989; 3: 303–311.
White WB, Lacourciere Y, Gana T, Pascual MG, Smith DH, Albert KS . Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. Am Heart J 2004; 148: 628–634.
Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788.
Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al., PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–2068.
Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 539–546.
Nakano S, Fukuda M, Hotta F, Ito T, Ishii T, Kitazawa M et al. Reversed circadian blood pressure rhythm is associated with occurrences of both fatal and nonfatal vascular events in NIDDM subjects. Diabetes 1998; 47 (9): 1501–1506.
Owens P, O'Brien E . Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events? Heart 1999; 82: 477–481.
Kario K, Matsuo T, Kobayashi H, Imiya M, Matsuo M, Shimada K . Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients. Advanced silent cerebrovascular damage in extreme dippers. Hypertension 1996; 27: 130–135.
Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K . Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 2001; 38: 852–857.
Acknowledgements
We thank Melaine Kite and Mike Ebanks for their help in data collection. We thank Dr Sunil Nadar for help with graphs.
Author information
Authors and Affiliations
Corresponding author
Additional information
This paper was dealt with by a Guest Editor, Associate Professor Bernard Cheung from the University of Hong Kong, and editorial decisions were independent of the Birmingham-based editor.
Rights and permissions
About this article
Cite this article
Goyal, D., Chong, A., Watson, R. et al. Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study. J Hum Hypertens 21, 525–530 (2007). https://doi.org/10.1038/sj.jhh.1002174
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002174